Details of the Drug

General Information of Drug (ID: DM05FXR)

Drug Name

Meclofenamic acid

Synonyms

Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Ankylosing spondylitis	FA92.0	Approved	[1]
Dysmenorrhea	GA34.3	Approved	[2]
Joint pain	ME82	Approved	[1]
Menorrhagia	GA20.50	Approved	[2]
Osteoarthritis	FA00-FA05	Approved	[3]
Pain	MG30-MG3Z	Approved	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

296.1

Logarithm of the Partition Coefficient (xlogp)

5.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability: 65.099998% of drug becomes completely available to its intended biological destination(s) [6]
Clearance: The oral clearance of drug []
Half-life: The concentration or amount of drug in body reduced by one-half in 0.8 - 5.3 hours (healthy subjects following a single oral dose) [7]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.295 micromolar/kg/day [8]
Vd: The volume of distribution (Vd) of drug is 9.1-43.2 L []

Chemical Identifiers

Formula: C14H11Cl2NO2
IUPAC Name: 2-(2,6-dichloro-3-methylanilino)benzoic acid
Canonical SMILES: CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl
InChI: InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
InChIKey: SBDNJUWAMKYJOX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4037
ChEBI ID: CHEBI:6710
CAS Number: 644-62-2
DrugBank ID: DB00939
TTD ID: D08IFL
INTEDE ID: DR2291
ACDINA ID: D00388

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN ; PGH2_HUMAN	Inhibitor	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 102A1 (cyp102)_{Main DME}	DE4OGUF	CPXB_BACMB	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[11]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[11]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[11]
Aldo-keto reductase family 1 member C4 (AKR1C4)	OTW2MMOF	AK1C4_HUMAN	Gene/Protein Processing	[12]
L-selectin (SELL)	OT6RAJZR	LYAM1_HUMAN	Gene/Protein Processing	[13]
Polyunsaturated fatty acid 5-lipoxygenase (ALOX5)	OT7FOIK2	LOX5_HUMAN	Gene/Protein Processing	[14]
Sulfotransferase 1A1 (SULT1A1)	OT0K7JIE	ST1A1_HUMAN	Gene/Protein Processing	[15]
Sulfotransferase 1E1 (SULT1E1)	OTGPJ517	ST1E1_HUMAN	Gene/Protein Processing	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Meclofenamic acid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[16]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Meclofenamic acid and Glibenclamide.	Acute diabete complication [5A2Y]	[17]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Meclofenamic acid and Glipizide.	Acute diabete complication [5A2Y]	[17]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Inotersen.	Amyloidosis [5D00]	[18]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[19]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Cilostazol.	Arterial occlusive disease [BD40]	[20]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meclofenamic acid and Budesonide.	Asthma [CA23]	[21]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Meclofenamic acid and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Kanamycin.	Bacterial infection [1A00-1C4Z]	[23]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS stimulant effects by the combination of Meclofenamic acid and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Streptomycin.	Bacterial infection [1A00-1C4Z]	[23]
Gemifloxacin	DMHT34O	Moderate	Additive CNS stimulant effects by the combination of Meclofenamic acid and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Meclofenamic acid and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
ABT-492	DMJFD2I	Moderate	Additive CNS stimulant effects by the combination of Meclofenamic acid and ABT-492.	Bacterial infection [1A00-1C4Z]	[22]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Netilmicin.	Bacterial infection [1A00-1C4Z]	[23]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Meclofenamic acid and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS stimulant effects by the combination of Meclofenamic acid and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Etidronic acid.	Bone paget disease [FB85]	[24]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[25]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[20]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Iodipamide.	Cholelithiasis [DC11]	[26]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Levomilnacipran.	Chronic pain [MG30]	[27]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Regorafenib.	Colorectal cancer [2B91]	[18]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Meclofenamic acid and Drospirenone.	Contraceptive management [QA21]	[28]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Ardeparin.	Coronary thrombosis [BA43]	[29]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Danaparoid.	Deep vein thrombosis [BD71]	[29]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Rivaroxaban.	Deep vein thrombosis [BD71]	[30]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Sertraline.	Depression [6A70-6A7Z]	[27]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Vilazodone.	Depression [6A70-6A7Z]	[27]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Vortioxetine.	Depression [6A70-6A7Z]	[27]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Milnacipran.	Depression [6A70-6A7Z]	[27]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Escitalopram.	Depression [6A70-6A7Z]	[27]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Desvenlafaxine.	Depression [6A70-6A7Z]	[27]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Clomipramine.	Depression [6A70-6A7Z]	[27]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Cannabidiol.	Epileptic encephalopathy [8A62]	[18]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Tazemetostat.	Follicular lymphoma [2A80]	[20]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[18]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Sulfinpyrazone.	Gout [FA25]	[20]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[31]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[32]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[33]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[34]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Meclofenamic acid when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[35]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Meclofenamic acid when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[35]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Dipyridamole.	Hypertension [BA00-BA04]	[20]
Balsalazide	DM7I1T9	Moderate	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Balsalazide.	Indeterminate colitis [DD72]	[36]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[37]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Idelalisib.	Mature B-cell leukaemia [2A82]	[19]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[38]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Ibrutinib.	Mature B-cell lymphoma [2A85]	[39]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Ponatinib.	Mature B-cell lymphoma [2A85]	[38]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Exjade.	Mineral absorption/transport disorder [5C64]	[40]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Panobinostat.	Multiple myeloma [2A83]	[41]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meclofenamic acid and Deflazacort.	Muscular dystrophy [8C70]	[21]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[20]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Dasatinib.	Myeloproliferative neoplasm [2A20]	[41]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[38]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Prasugrel.	Myocardial infarction [BA41-BA43]	[18]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Vorapaxar.	Myocardial infarction [BA41-BA43]	[42]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Sibutramine.	Obesity [5B80-5B81]	[27]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Dexfenfluramine.	Obesity [5B80-5B81]	[27]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Meclofenamic acid when combined with Polythiazide.	Oedema [MG29]	[35]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and MK-4827.	Ovarian cancer [2C73]	[18]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meclofenamic acid and Aspirin.	Pain [MG30-MG3Z]	[43]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Epoprostenol.	Pulmonary hypertension [BB01]	[44]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Iloprost.	Pulmonary hypertension [BB01]	[44]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Everolimus.	Renal cell carcinoma [2C90]	[45]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Temsirolimus.	Renal cell carcinoma [2C90]	[45]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Meclofenamic acid and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[22]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meclofenamic acid and Dexamethasone.	Rheumatoid arthritis [FA20]	[21]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Leflunomide.	Rheumatoid arthritis [FA20]	[33]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meclofenamic acid and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[21]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Meclofenamic acid and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meclofenamic acid and Pitolisant.	Somnolence [MG42]	[18]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Caplacizumab.	Thrombocytopenia [3B64]	[20]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Apixaban.	Thrombosis [DB61-GB90]	[18]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Cangrelor.	Thrombosis [DB61-GB90]	[20]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Meclofenamic acid and Brilinta.	Thrombosis [DB61-GB90]	[18]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Meclofenamic acid and Cabozantinib.	Thyroid cancer [2D10]	[46]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Meclofenamic acid and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[17]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Olsalazine.	Ulcerative colitis [DD71]	[36]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Meclofenamic acid and Plazomicin.	Urinary tract infection [GC08]	[23]
-----------


⏷ Show the Full List of 82 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
FD&C red no. 3	E00629	Not Available	Colorant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Meclofenamic acid 100 mg capsule	100 mg	Oral Capsule	Oral
Meclofenamic acid 50 mg capsule	50 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7219).
2	Use of meclofenamic acid in gynecology and obstetrics: effects on postsurgical stress. Clin J Pain. 1991;7 Suppl 1:S60-3.
3	Quantitation of indomethacin in serum and plasma using gas chromatography-mass spectrometry (GC-MS). Methods Mol Biol. 2010;603:297-305.
4	Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer. Front Oncol. 2022 Apr 21;12:870636.
5	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
6	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
10	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
11	Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
12	Initro CAPE inhibitory activity towards human AKR1C3 and the molecular basis. Chem Biol Interact. 2016 Jun 25;253:60-5.
13	Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem. 2002 Oct 11;277(41):38212-21. doi: 10.1074/jbc.M205142200. Epub 2002 Jul 29.
14	Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38.
15	Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
16	European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
17	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
18	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19	Product Information. Hivid (zalcitabine). Roche Laboratories, Nutley, NJ.
20	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
21	Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4. [PMID: 6343871]
22	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
23	Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
24	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
25	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
26	Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74. [PMID: 20502171]
27	Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
28	Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70. [PMID: 2865667]
29	Product Information. Lovenox (enoxaparin). Rhone-Poulenc Rorer, Collegeville, PA.
30	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
31	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
32	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
33	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
34	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
35	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
36	Product Information. Canasa (mesalamine (5-aminosalicylic acid)). Axcan Scandipharm Inc, Birmingham, AL.
37	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
38	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
39	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
40	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
41	Cerner Multum, Inc. "Australian Product Information.".
42	Product Information. Zontivity (vorapaxar). Merck &amp Company Inc, Whitehouse Station, NJ.
43	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
44	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
45	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
46	Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]